November 19, 2024

New J&J Pill Clears Psoriasis in Trials

Reuters

November 18, 2024

RFK Jr. Calls Fluoride 'Industrial Waste'

"On January 20, the Trump White House will advise all U.S. water systems to remove fluoride from public water."

KFF Health News

November 04, 2024

FTC Finalizes "Click-to-Cancel" Rule

FTC finalizes rule requiring subscription-based businesses to provide cancellation processes as simple as enrollment methods, effective 180 days after Federal Register publication.

Conexiant

October 31, 2024

FDA Grants New EB Treatment Designation

Squamous cell carcinoma is the leading cause of mortality in severe epidermolysis bullosa," notes Dr. Robert Kirsner, as FDA grants rare pediatric designation to mitochondrial-targeting therapy.

Conexiant

April 29, 2024

Record Heat Waves Propel Surge in Heat-Related Illness

2023 brought record-breaking heat waves in the United States, significantly impacting vulnerable groups. Analysis by the CDC revealed a substantial number of heat-related illness (HRI) emergency department visits, resulting in multiple public health alerts.

Conexiant

June 20, 2024

FDA Proposes Removal of Switching Study Requirement for Biosimilars

Explore the FDA's proposed changes for biosimilar drugs and their interchangeability, including expert insights on regulatory impacts and market dynamics.

Reuters

September 30, 2024

Lupus Treatment Trial Paused Following Patient Deaths

Three of the fatalities showed a common pattern of symptoms and the deaths happened close to the time of dosing, while a non-fatal adverse event showed a similar proximity to dosing.

Reuters

April 29, 2024

FDA Boxed Warning Outlines Risk of Hypocalcemia in Patients Taking Denosumab

The U.S. Food and Drug Administration (FDA) has added a boxed warning to the label of denosumab after finding that the osteoporosis drug may cause severe hypocalcemia in patients with advanced chronic kidney disease.

Conexiant

June 26, 2024

FDA Releases Guidance for Drugmakers on Diversity in Clinical Studies

The U.S. Food and Drug Administration issued draft guidance for drugmakers and medical device makers to improve diversity in clinical trials, emphasizing the importance of actions to support more equitable access to medical innovations.

Conexiant